GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024

- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment SEOUL, South Korea, Oct. 29, 2024 /PRNewswire/ -- GemVax & KAEL Co., Ltd. ("GemVax"; KOSDAQ ticker: 082270) announced that topline results of a Phase 2a clinical trial (the...